| Year |
Citation |
Score |
| 2022 |
Garzón-Porras AM, Chory E, Gryder BE. Dynamic Opposition of Histone Modifications. Acs Chemical Biology. PMID 35297606 DOI: 10.1021/acschembio.1c01000 |
0.306 |
|
| 2021 |
Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, et al. Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Blood Cancer Discovery. 2: 370-387. PMID 34258103 DOI: 10.1158/2643-3230.BCD-20-0108 |
0.315 |
|
| 2020 |
Adelaiye-Ogala R, Gryder BE, Nguyen YTM, Alilin AN, Grayson AR, Bajwa W, Jansson KH, Beshiri ML, Agarwal S, Rodriguez-Nieves JA, Capaldo B, Kelly K, VanderWeele DJ. Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor. Molecular Cancer Therapeutics. PMID 32371590 DOI: 10.1158/1535-7163.Mct-19-0936 |
0.382 |
|
| 2019 |
Gryder BE, Wu L, Woldemichael GM, Pomella S, Quinn TR, Park PMC, Cleveland A, Stanton BZ, Song Y, Rota R, Wiest O, Yohe ME, Shern JF, Qi J, Khan J. Chemical genomics reveals histone deacetylases are required for core regulatory transcription. Nature Communications. 10: 3004. PMID 31285436 DOI: 10.1038/S41467-019-11046-7 |
0.323 |
|
| 2013 |
Gryder BE, Akbashev MJ, Rood MK, Raftery ED, Meyers WM, Dillard P, Khan S, Oyelere AK. Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. Acs Chemical Biology. 8: 2550-60. PMID 24004176 DOI: 10.1021/cb400542w |
0.677 |
|
| 2013 |
Gryder BE, Rood MK, Johnson KA, Patil V, Raftery ED, Yao LP, Rice M, Azizi B, Doyle DF, Oyelere AK. Histone deacetylase inhibitors equipped with estrogen receptor modulation activity. Journal of Medicinal Chemistry. 56: 5782-96. PMID 23786452 DOI: 10.1021/Jm400467W |
0.648 |
|
| 2012 |
Dreaden EC, Gryder BE, Austin LA, Tene Defo BA, Hayden SC, Pi M, Quarles LD, Oyelere AK, El-Sayed MA. Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjugate Chemistry. 23: 1507-12. PMID 22768914 DOI: 10.1021/Bc300158K |
0.559 |
|
| 2012 |
Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Medicinal Chemistry. 4: 505-24. PMID 22416777 DOI: 10.4155/fmc.12.3 |
0.632 |
|
| 2010 |
Patil V, Guerrant W, Chen PC, Gryder B, Benicewicz DB, Khan SI, Tekwani BL, Oyelere AK. Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. Bioorganic & Medicinal Chemistry. 18: 415-25. PMID 19914074 DOI: 10.1016/J.Bmc.2009.10.042 |
0.429 |
|
| Show low-probability matches. |
